Clinical Trials /

Natural Killer Cell (CYNK-001) Infusions in Adults With AML

NCT04310592

Description:

This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.

Related Conditions:
  • Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia
Recruiting Status:

Recruiting

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Natural Killer Cell (CYNK-001) Infusions in Adults With AML
  • Official Title: Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Primary or Secondary AML in Morphologic Complete Remission With Minimal Residual Disease

Clinical Trial IDs

  • ORG STUDY ID: CYNK-001-AML-001
  • NCT ID: NCT04310592

Conditions

  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myeloid, Acute
  • Neoplasms by Histologic Type
  • Neoplasms
  • Immunosuppressive Agents
  • Immunologic Factors
  • Physiological Effects of Drugs
  • Alkylating Agents
  • Antimetabolites, Antineoplastic
  • Antiviral Agents
  • Analgesics, Non-narcotic
  • Anti-infective Agents
  • Analgesics
  • Peripheral Nervous System Agents
  • Hematologic Diseases
  • Hematologic Neoplasms
  • Leukemia in Remission

Interventions

DrugSynonymsArms
CYNK-001Dose escalation/MTD or MPD determination

Purpose

This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.

Trial Arms

NameTypeDescriptionInterventions
Dose escalation/MTD or MPD determinationExperimentalCyclophosphamide + Fludarabine prior to CYNK-001 on Days 0, 7, and 14; CYNK-001 at 3 varying dose levels.
  • CYNK-001

Eligibility Criteria

        Treatment Eligibility Screening Patient Inclusion Criteria

        Patients must satisfy the following criteria to be enrolled in the study:

          -  Patient has eligible disease status: Primary or Secondary acute myeloid leukemia (AML)
             Patients in first of second Morphological Complete Remission (CR), Morphological
             Complete Remission with incomplete hematologic recovery (CRi), or Morphologic
             Leukemia-free State (MLFS) as defined by the European LeukemiaNet (ELN)
             recommendations for AML Response Criteria (Dohner, 2017).

          -  Patient with prior central nervous system involvement by malignancy are eligible
             provided that it has been treated and cerebral spinal fluid is clear for at least 2
             weeks prior to start of Lymphodepletion Regimen.

          -  Patient is minimal residual disease (MRD) positive, as assessed on bone marrow
             aspirate (BMA) by Multiparameter Flow Cytometry (MFC) at time of Treatment Eligibility
             assessment.

             o For the purposes of this study, MRD positivity is defined as greater than or equal
             to 0.1% blasts detected by MFC on BMA by the Sponsor-selected Central MRD analysis
             laboratory, where assay sensitivity allows for a Lower Limit of Detection (LOD) of 1 x
             10-4 (0.01%) or lower.

          -  Patient is ≥ 18 and ≤ 80 years of age at the time of signing the Study informed
             consent form (ICF).

          -  Patient understands and voluntarily signs the Study ICF prior to any study-related
             assessments/procedures are conducted.

          -  Patient is willing and able to adhere to the study schedule and other protocol
             requirements.

          -  Performance status of Eastern Cooperative Oncology Group (ECOG) ≤ 2.

          -  Ability to be off immunosuppressive drugs for at least 3 days prior to the CYNK-001
             infusion. Steroids at the equivalent of no more than 7.5 mg prednisone per day are
             permissible.

          -  Female of childbearing potential (FCBP)* must not be pregnant and agree to not
             becoming pregnant for at least 28 days following the CYNK-001. FCBP must agree to use
             an adequate method of contraception during the treatment period.

               -  FCBP is a female who: 1) has achieved menarche at some point, 2) has not
                  undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally
                  postmenopausal (amenorrhea following cancer therapy does not rule out
                  childbearing potential) for at least 24 consecutive months (i.e., has had menses
                  at any time in the preceding 24 consecutive months).

          -  Male Patients must agree to use a condom during sexual contact for at least 28 days
             following the last infusion of CYNK-001, even if he has undergone a successful
             vasectomy.

        Treatment Eligibility Screening Patient Exclusion Criteria

        The presence of any of the following will exclude the Patient from enrollment:

          -  Patient has any significant medical condition, laboratory abnormality, or psychiatric
             illness that would prevent the Patient from participating in the study.

          -  Patient has any condition including the presence of laboratory abnormalities which
             places the Patient at unacceptable risk if he or she were to participate in the study.

          -  Patient has any condition that confounds the ability to interpret data from the study.

          -  Patient has bi-phenotypic acute leukemia.

          -  Patient has acute promyelocytic leukemia (APL).

          -  Patient has inadequate organ function as defined below at time of Treatment
             Eligibility Period:

               1. Patient has aspartate aminotransferase (AST), alanine aminotransferase (ALT), or
                  alkaline phosphatase ≥ 2.5 x the upper limit of normal (ULN).

               2. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 as calculated
                  using the Modification of Diet in Renal Disease Study equation (Levey, 2006) or
                  history of an abnormal eGFR < 60 and a decline of > 15 mL/min/1.73 m2 below
                  normal in the past year.

               3. Patient has a bilirubin level > 2 mg/dL (unless Patient has known Gilbert's
                  disease).

          -  Patient has had prior treatment with biologic antineoplastic agents less than 7 days
             before first CYNK-001 infusion and at least 5 half-lives. (Exception will be granted
             for monoclonal antibodies that are known to have long half-lives, in which case a
             minimum of 2 weeks from last dose will be required). For agents that have known AEs
             occurring beyond these specified days after administration, this period must be
             extended beyond the time during which acute AEs are known to occur. Treating
             physicians are encouraged to discuss cases with the Medical Monitor.

          -  Patient is pregnant or breastfeeding.

          -  Patient has new or progressive pulmonary infiltrates or pleural effusion large enough
             to be detected by chest x-ray or CT scan within 2 weeks of first CYNK-001 infusion.

          -  Patient has active autoimmune disease other than controlled connective tissue disorder
             or those who are not on active therapy.

          -  Patient has had a Bone Marrow transplant as part of their anti-AML treatment prior to
             first CYNK-001 infusion or plans to have transplant within the 28 day period following
             first CYNK-001 infusion. Exception includes relapsed patients who received prior Bone
             Marrow transplant as part of their treatment plan at initial diagnosis.

          -  Patient has a history of malignancy other than AML or other underlying hematologic
             conditions such as myelodysplastic syndromes (MDS) or myeloproliferative neoplasms
             (MPN) unless the Patient has been free of disease for greater than 3 years prior to
             CYNK 001 infusion. Exceptions will include the following malignancies:

               1. Basal cell carcinoma of the skin

               2. Squamous cell carcinoma of the skin

               3. Carcinoma in situ of the cervix

               4. Carcinoma in situ of the breast

               5. Incidental biological finding of prostate cancer (TNM stage of T1a or T1b)

          -  Patient has a history of severe asthma and is presently on chronic medications or has
             a history of other symptomatic pulmonary disease.

          -  Patient has uncontrolled graft versus host disease (GVHD) or GVHD requiring treatment
             with corticosteroids.

          -  Patient has an untreated chronic infection or has received treatment of any infection
             with systemic antibiotics within 2 weeks prior to first CYNK-001 infusion.
             Prophylactic antibiotic, antiviral, and antifungal medication are permissible.

          -  Patient has any other organ dysfunction (CTCAE Version 5.0 Grade 3 or greater) that
             will interfere with the administration of the therapy according to this protocol.

          -  Patient has a resting left ventricular ejection fraction (LVEF) of < 45% obtained by
             echocardiography or multi-gated acquisition scan (MUGA).

          -  Patient was treated with an investigational product within 28 days of first CYNK-001
             infusion. Patient must no longer be a participant in the previous interventional study
             at the time of CYNK-001 infusion. (Patients who are under survival follow-up or
             observation associated with a study are permitted, and if treatment information is
             collected for this period, "Investigational Study" must be used to capture the study
             treatment.).
      
Maximum Eligible Age:80 Years
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Number of Participants who experience a Dose-limiting Toxicity (DLT)
Time Frame:Day +28
Safety Issue:
Description:The number of participants who experience a DLT will be measured.

Secondary Outcome Measures

Measure:Number of Participants who experience Minimal Residual Disease (MRD) Response
Time Frame:up to 12 months
Safety Issue:
Description:The number of participants who convert from MRD positive to MRD negative.
Measure:Time to MRD Response
Time Frame:up to 12 months
Safety Issue:
Description:The time it takes to convert from MRD positive to MRD negative.
Measure:Duration of MRD Response
Time Frame:up to 12 months
Safety Issue:
Description:The measure of how long participants remain MRD negative.
Measure:Progression-free Survival (PFS)
Time Frame:up to 12 months
Safety Issue:
Description:Date of first CYNK-001 infusion to date of disease progression.
Measure:Time to Progression (TTP)
Time Frame:up to 12 months
Safety Issue:
Description:Date of first CYNK-001 infusion to date of disease progression.
Measure:Duration of Morphologic Complete Remission (CR)
Time Frame:up to 12 months
Safety Issue:
Description:Duration from first Morphologic CR observation to time of disease progression.
Measure:Overall Survival (OS)
Time Frame:up to 12 months
Safety Issue:
Description:Date of first CYNK-001 infusion to date of death.

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Celularity Incorporated

Trial Keywords

  • CYNK-001
  • Acute Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • allogeneic
  • allogeneic stem cell transplant
  • AML
  • cell therapy
  • cyclophosphamide
  • fludarabine
  • minimal residual disease
  • MRD
  • newly diagnosed AML
  • newly diagnosed acute myeloid leukemia
  • NK cells
  • natural killer cells
  • fludarabine phosphate
  • antineoplastic agents, alkylating
  • molecular mechanisms of pharmacological action

Last Updated

July 28, 2020